Strategic Transformation Supports Roquette’s H1 2026 Performance

Strategic Transformation Supports Roquette’s H1 2026 Performance

• +9% turnover growth to €2,586 million and +18% Current EBITDA increase to €337 million. Performance was supported by favorable volume and mix effects, the continued contribution of an enhanced portfolio, and the first positive results from Shift & Lead, which is already delivering ahead of target.
  • Sales of cellulose and alginates for pharmaceutical and healthcare applications supported performance, despite ongoing challenging market conditions in the starch industry.
  • The strategic ramp-up in proteins and fibers for the food and nutrition business continues to develop in line with expectations.
  • Strong commercial performance in India and China, two key strategic markets for Roquette.
• +101 bps increase in Current EBITDA margin to 13.0%, driven by pharma, food and nutrition segments and disciplined cost management.
• Free Cash-Flow improved to -€54 million, to be compared with -€150 million in H1 2025 (excluding the cash impact of the IFF Pharma Solutions acquisition).
• Successful issuance of €600 million of perpetual hybrid bonds¹ in April 2026 to further strengthen Roquette’s financial position. 
  
  

Lille – September 24^th, 2026 – Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, today announced its H1 2026 results, following the approval of its financial statements by the Board of Directors.

Thierry Fournier, CEO of Roquette, commented: “In a market environment that remains challenging, dynamic and competitive, Roquette’s performance was supported by the contribution of new product lines, especially in the pharma and healthcare segment. While like-for-like performance remains impacted by the aforementioned market conditions, we are encouraged by the early progress of Shift & Lead, the company’s strategic plan, which is helping us to position the Group for long-term growth.”

Cellulose and Alginates Drive HPS’ Performance

Within the Health & Pharma Business Unit, the starch and capsules businesses continued to face headwinds from ongoing competition and price pressure. This was partially offset by the contribution of Roquette’s cellulose and alginates product lines which delivered strong performance in H1 2026. This reflects the relevance of the company’s strategy to expand its portfolio and develop value-added solutions that address evolving customer and patient needs.

Proteins and Fibers Support NBI’s Strategic Growth Ambitions

Despite persistent market headwinds affecting the Nutrition & Bioindustry Business Unit, Roquette’s proteins and fibers businesses continued to develop in line with expectations, with strong momentum in Europe and North America. The proteins business recorded growth in volumes and sales compared to the first half of 2025, reflecting the execution of Roquette’s ambition to become a reference in high-value pea ingredients. More broadly across the Business Unit, performance was especially strong across Asia, where progress in India continued alongside sustained momentum throughout the region.

Shift & Lead Delivering Early Results

In early 2026, Roquette launched Shift & Lead, the Group's strategic transformation plan designed to strengthen competitiveness, accelerate performance and support long-term value creation.

"In an evolving and demanding market environment, we recognized the need to act decisively and responsibly. This is why we launched Shift & Lead: to ensure Roquette remains well positioned for the future while continuing to create value for customers, employees, partners and shareholders. I have been impressed by the speed and commitment of our teams in bringing this plan to life - it has already delivered more than €60m in just a few months. Across the Group, we are fostering new ways of thinking and working, with a clear focus on operational excellence, agility and performance. We remain confident in our ability to capture future opportunities and build on the strengths that have long defined Roquette," concluded Thierry Fournier.

HALF YEAR 2026 CONSOLIDATED KEY FIGURES²

^{(a) Excluding non-recurring items amounting to €59 million (€164 million in H1 25) and associated taxes.
(b) excluding IFF Pharma Solutions, acquired on May 1st, 2025.
(c) Net debt IFRS / Combined Current EBITDA (which includes IFF Pharma Solutions estimated Current EBITDA over the last twelve months).}

FINANCIAL PERFORMANCE

RESILIENT H1 2026 RESULTS AMID PERSISTENT MARKET HEADWINDS

Throughout the first half of 2026, Roquette navigated a global environment that remained highly demanding, shaped by just a modest recovery in underlying demand, intensifying competitive pressure, and unfavorable foreign exchange conditions, as the euro strengthened against the US dollar compared to the first half of 2025. The period was also impacted by macroeconomic and geopolitical uncertainty, notably through the energy and chemical cost volatility triggered by the Iran conflict.

Despite these persistent market headwinds, Roquette's turnover reached €2,586 million in H1 2026, up 9% year-on-year, primarily reflecting the full six-month contribution of cellulose & alginates pharmaceutical excipients, which were consolidated for only two months in the prior-year comparative. On a like-for-like (LFL³) basis, volumes increased by 2% over the period, reflecting resilient underlying demand. Nevertheless, like-for-like turnover was down 2%, reflecting the continued challenging market environment across several of the Group's core commodity segments.

Current EBITDA rose 18% to €337 million, compared with €285 million in H1 2025, with Current EBITDA margin improving by 101 basis points to 13.0%, driven by solid growth in new product lines. Excluding perimeter and currency effects, Current EBITDA declined 2% and the margin contracted by 2 basis points, as volume resilience and continued discipline under the Group's Shift & Lead cost programme were more than offset by adverse pricing, notably on liquid sugars, starches and powder polyols.

The cost of net financial debt amounted to €59 million, reflecting the Group's post-acquisition financing structure.
Non-recurring items include mainly IFF Pharma Solutions acquisition and integration costs for €20 million and a provision of €28 million for restructuring costs.
As a result, the reported net result turned positive at €17 million, compared with a net loss of €115 million in H1 2025, which had been weighed down by non-cash impairment charges (€122 million) and IFF Pharma Solutions and Qualicaps acquisition and integration costs (€52 million).

Excluding non-recurring items and the associated taxes, the adjusted net result amounted to €61 million compared to €42 million at end of June 2025.

Against a backdrop of persistent geopolitical and macroeconomic uncertainty, sustained competitive intensity, and continued FX volatility, the Group maintained its focus on operational efficiency and cost discipline. At the same time, the Group remained focused on deleveraging, with net debt down €530 million since December 2025, notably benefiting from the successful hybrid bond transaction, and leverage improving to 2.80x.

FREE CASH-FLOW GENERATION

Free Cash-Flow stood at -€54 million in H1 2026, a marked improvement from -€150 million in H1 2025 (before the IFF Pharma Solutions acquisition cash impact). This performance was driven by several key factors:

• Operating Cash-Flow came in at €165 million, versus €186 million in H1 2025, mainly impacted by a higher cost of financial debt and hybrid bond coupons, partly offset by lower cash outflows on non-recurring items. Excluding financing-related effects, cash generation benefited from the Group's improved operating performance, driven by EBITDA growth.
• Working Capital Requirement improved significantly, with the related cash outflow reduced to €94 million from €223 million in H1 2025, driven primarily by a €127 million reduction in inventories across both Business Units. Factored receivables remained consistent with the quantum at December 31, 2025. Given the seasonal profile of the business, Working Capital Requirement is typically significantly higher at the end of June than at year-end. However, the ongoing benefits from the Group's Shift & Lead working capital initiatives have contributed to an improved Working Capital Requirement position compared with prior years.
• Capital expenditures amounted to €125 million, broadly stable versus €114 million in H1 2025, a modest increase mainly attributable to perimeter effect.
  
  

PERFORMANCE BY BUSINESS UNIT

HEALTH & PHARMA SOLUTIONS – CELLULOSE & ALGINATES ANCHOR A DIVERSIFIED PORTFOLIO

Sales for the Health & Pharma Solutions Business Unit reached €852 million, up 56% year-on-year, reflecting the full six-month contribution of cellulose & alginates product lines. Current EBITDA rose 40% to €196 million, representing a margin of 23.0%.

Cellulose and alginates delivered a strong performance, led by ethyl cellulosics, oral drug-delivery disintegrant technologies and the alginates product lines. Excluding perimeter and currency effects, Current EBITDA declined by 12%, as the legacy starch business continued to face intensifying competition on polyols, notably in Europe, together with the impact of plant maintenance activities as well as weather-related disruptions affecting alginates. The capsules and equipment businesses remained under pressure, penalised by softer contract adherence and a shortfall in HPMC capsules volumes, though phasing effect related to capsules equipment is expected to reverse in H2.

The Business Unit’s overall performance illustrates the relevance of the Group's strategy to diversify across drug-delivery technologies, allowing HPS to absorb pressure in specific segments while capturing growth in higher-value pharmaceutical applications.

NUTRITION AND BIOINDUSTRY – MARGIN DISCIPLINE IN A DEMANDING COMMODITY CYCLE

Sales for the Nutrition & Bioindustry Business Unit amounted to €1,888 million, down 2% both on a reported and like-for-like basis, while Current EBITDA reached €141 million. On a like-for-like basis, Current EBITDA rose 8% and the margin improved 75 basis points, reflecting a favourable mix effect and noticeable decline in raw material prices in China and India.

Asia delivered a particularly strong performance, with progress in China and India supporting robust volume growth across the region. The proteins and fibers product lines reported solid growth. In Europe, volumes remained resilient in food specialties, although this was achieved against a backdrop of intense pricing pressure on commodities – mainly liquid sugars, powder polyols and modified starches – reflecting the continued impact of historically low sugar prices in Europe and strong competition. North America remained the Business Unit's principal area of challenge, with industrial reliability issues, higher maintenance costs and continued pressure on liquid sugars weighing on fixed costs absorption and profitability.

This performance confirms the Business Unit's capacity to capture value in high-growth categories, proteins, fibers and Asian markets, even as broader commodity markets remain highly competitive.

BALANCE SHEET

^{(a) Net debt IFRS / Combined Current EBITDA (which includes IFF Pharma Solutions estimated EBITDA over the last twelve months).}

Strengthened balance sheet and improved financial flexibility

Roquette maintained a solid financial position during the first half of 2026, supported by disciplined working capital management, inventory optimization initiatives and strong collection performance. The successful issuance of €600 million of perpetual hybrid bonds in April 2026 further strengthened the Group’s capital structure and financial flexibility.

At June 30, 2026, the Group’s net financial debt stood at €1,860 million, compared with €2,390 million at December 31, 2025. This reduction reflects strong cash discipline, working capital optimization and the use of hybrid bond proceeds to refinance part of the acquisition financing put in place for IFF Pharma Solutions, including the full repayment of the €275 million IFF euro term loan and the early repayment of most of the Qualicaps term loan.

Consequently, the restated IFRS leverage ratio improved to 2.80x, compared with 3.48x at December 31, 2025. The Group continues to benefit from a balanced debt maturity profile and significant headroom under its financial covenants.

The Group reaffirms the IFRS leverage ratio target of 2.3x to 2.7x by 2027, remaining fully committed to maintaining a strong Investment Grade rating.

Status of the accounts:
The limited review procedures on the H1 2026 consolidated financial statements have been completed. The certification report is currently being issued and is scheduled for September 25th, 2026.

About Roquette

Roquette is a global leader in sustainable plant-based solutions, driving innovation and strong partnerships that are shaping the future of nutrition, health, and bioindustry.

The company harnesses natural resources such as wheat, corn, seaweed, and cellulose to craft high-performance ingredients used in everyday foods, oral medications, advanced biopharmaceuticals, and a range of bio-based products.

A family-owned company with over 90 years of expertise and 11,000 employees, Roquette serves clients in over 150 countries and is committed to creating lasting value for customers, patients, consumers, and society.

Together, we turn the potential of nature into the essentials of life.

Discover more about Roquette here.

Press contacts:
Brunswick
Aurélia de Lapeyrouse
+33 (0) 6 21 06 40 33
adelapeyrouse@brunswickgroup.com

Roquette
Corporate Communications
Susannah Duquesne
Susannah.duquesne@roquette.com

Financial Communications
Cécile Masurel
cecile.masurel@roquette.com

DISCLAIMER - Certain statements contained in this press release may contain forecasts that specifically relate to future events, trends, plans or objectives. By nature, these forecasts involve identified and unidentified risks and uncertainties and may be affected by many factors likely to give rise to a significant discrepancy between the actual results and those indicated in these statements. The group does not undertake to publish an update or revision of these forecasts, or to communicate on new information, future events or any other special circumstance. The amounts presented in this presentation have been rounded to the nearest hundred/unit, which may result in slight discrepancies in totals. Thus, the financial data is provided for informational purposes only and may not exactly match the figures in the consolidated financial statements.

FINANCIAL INFORMATION - This press release and Roquette's full regulated information are available on the Group's website: www.roquette.com

GLOSSARY

To measure its performance, the Group uses certain financial indicators that are not defined by IFRS standards. These indicators are used in the operational monitoring of the Group’s activities and its financial communication (press releases, financial presentations, etc.).

APPENDIX 1 – INCOME STATEMENT

APPENDIX 2 – COMPREHENSIVE INCOME STATEMENT

APPENDIX 3 – BALANCE SHEET

APPENDIX 4 – CASH-FLOW STATEMENT

APPENDIX 5 – GROSS DEBT TOWARDS FINANCIAL INSTITUTIONS

¹ Press Release: Roquette Successfully Prices its Hybrid Notes Issuance for an Amount of 600 million Euros
² The definition of the alternative performance indicators is provided in the appendices of this press release.
³ Like-For-Like basis excludes exchange rates impact and perimeter variation.